Interest in peptides has grown rapidly in anti-aging and hormone optimization circles. Walk into any longevity clinic today and you’ll hear names like sermorelin peptide, BPC-157, ipamorelin, and CJC-1295 tossed around as if they are interchangeable. They are not.
These compounds differ in how they work, what they target, how long they stay active in the body, and what evidence exists to support their use. Understanding those differences is the first step in having a meaningful conversation with your healthcare provider. This article is purely educational and does not constitute medical advice or make therapeutic claims about any product. Below, we compare sermorelin vs. tesamorelin, ipamorelin, CJC-1295, BPC-157, and HGH.
What Are Peptides?
Peptides are short chains of amino acids, the same building blocks that make up proteins. Your body already produces thousands of them naturally. Each one acts as a biological signal, telling tissues, glands, and organs what to do.
In the context of anti-aging and hormone optimization, the peptides that attract the most attention are those that interact with the growth hormone axis. Human growth hormone (HGH) plays a central role in body composition, metabolism, muscle mass, fat loss, and cellular repair. Growth hormone levels decline with age, which is why supporting the GH axis has become a focus for longevity-minded individuals.
Rather than injecting synthetic HGH directly, which bypasses the body’s own feedback systems, many clinicians now favor peptides that work with the pituitary gland to stimulate the body’s own growth hormone release. Sermorelin is the most established of these.
What Is the Sermorelin Peptide?
Sermorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). It consists of the first 29 amino acids of the naturally occurring GHRH molecule, the shortest sequence that retains full biological activity. Sermorelin binds to GHRH receptors on the pituitary gland and prompts a pulsatile release of growth hormone that closely mirrors the body’s natural rhythms.
Because sermorelin works upstream of the pituitary gland rather than delivering GH directly, the body’s own somatostatin feedback mechanism remains intact. This means the pituitary still regulates how much GH it releases.
Regulatory history: Sermorelin was previously FDA-approved under the brand name Geref, which its manufacturer later discontinued. Today it is available in the U.S. as a compounded medication prepared by licensed pharmacies with a prescription.
Learn more about Olympia’s Sermorelin Acetate 0.9 mg/mL injection.
Sermorelin vs. Ipamorelin
Ipamorelin is not a GHRH analogue. It is a growth hormone secretagogue that works by binding to the ghrelin receptor (GHS-R) in the pituitary gland and hypothalamus, the same receptor targeted by the hunger hormone ghrelin. This produces short, acute pulses of GH release rather than a sustained elevation.
Ipamorelin stimulates GH release without meaningfully raising cortisol, prolactin, or acetylcholine.
Key differences:
- Receptor: Sermorelin acts on the GHRH receptor. Ipamorelin acts on the ghrelin receptor (GHS-R1a).
- Signal: Sermorelin mimics the body’s own “release” signal from the hypothalamus. Ipamorelin triggers growth hormone release through a separate pathway.
- Regulatory status: Sermorelin was previously FDA-approved. Ipamorelin has never been FDA-approved, and its status for compounding has changed several times in recent years. Ask your pharmacist about its current status.
Because they act on different receptors, the two are sometimes discussed together. Whether either is appropriate is a decision for a licensed provider.
Sermorelin vs. CJC-1295
Like sermorelin, CJC-1295 is a GHRH analogue. However, it has been structurally modified to bind to albumin in the bloodstream, which dramatically extends its half-life to approximately six to eight days (with DAC formulation). This means injections are needed only once or twice a week rather than daily.
Sermorelin vs. Tesamorelin
Tesamorelin is also a GHRH analog, so it signals the pituitary gland in the same basic way sermorelin does. The difference is structural and regulatory. Tesamorelin is based on the full 44-amino-acid GHRH sequence with a modification that makes it more stable, while sermorelin uses only the first 29 amino acids.
Tesamorelin is FDA-approved under the brand names Egrifta SV and Egrifta WR for one specific use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. Because an FDA-approved version exists, compounding tesamorelin is restricted.
Sermorelin vs. HGH
Human growth hormone (HGH, or somatropin) is growth hormone itself, and FDA-approved somatropin products supply it directly. Sermorelin does not contain growth hormone. It signals the pituitary gland to release the body’s own growth hormone, and the body’s normal feedback controls continue to regulate that release. Both require a prescription, and which approach is appropriate, if any, is a clinical decision for a licensed provider.
Sermorelin vs. BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Its mechanism is completely different from any of the GH-axis peptides described above. Rather than stimulating hormone release, BPC-157 appears to work primarily through nitric oxide pathways, angiogenesis, and local tissue repair mechanisms.
Most research on BPC-157 has been done in animals, where it has been studied in tendon, gut, and other tissue models. Human data is still limited.
BPC-157 is not FDA-approved. Its status for pharmacy compounding has been under active review by FDA and HHS and changed several times in 2026, so ask your pharmacist about current availability. BPC-157 is also prohibited by the World Anti-Doping Agency (WADA).
| Sermorelin peptide | BPC-157 | |
| Primary Focus | Systemic GH axis support | Studied for local tissue repair |
| Mechanism | GHRH analogue → pituitary stimulation | Nitric oxide, angiogenesis, anti-inflammation |
| Target | Whole-body (metabolic, body composition) | Studied in tendon, gut, and joint models |
| FDA Status | Compounded (Rx only) | Not FDA-approved; compounding status under review |
| WADA Status | Prohibited in sport | Prohibited (S0 category) |
Key Considerations Before Exploring Peptide Therapy
For anyone researching peptides, a few points are worth keeping front of mind:
- Peptide therapy requires a clinician. None of the compounds discussed here should be used without medical supervision, a thorough health history review, and appropriate lab testing including growth hormone levels and IGF-1.
- Lifestyle factors matter. Results from any peptide protocol depend heavily on sleep, nutrition, exercise, and stress management. No peptide substitutes for foundational health habits.
- Human clinical data is limited for most peptides discussed here. Sermorelin has the longest history of clinical use among them.
- Source quality matters. Many peptides sold online are not made under pharmaceutical standards for quality, purity, and sterility. Use a licensed pharmacy such as Olympia Pharmaceuticals.
- Regulatory status varies and is changing. Sermorelin is available through compounding pharmacies with a prescription. Tesamorelin is FDA-approved for one specific use. BPC-157’s compounding status has been under review throughout 2026; ask your pharmacist for the latest.
- Dosing is individualized. For how Olympia’s sermorelin injection converts from mcg to mL and syringe units, see our Sermorelin Dosage Chart.
The Bottom Line
Sermorelin, ipamorelin, CJC-1295, tesamorelin, BPC-157, and HGH differ in what they are, how they work, how long they last, and where they stand with the FDA. Sermorelin’s defining feature is that it closely mimics the body’s natural GHRH signal while leaving the pituitary’s own feedback controls in place.
BPC-157 is a different kind of compound: a tissue-focused peptide studied mainly in animal research, with limited human data so far. It is not FDA-approved, and its compounding status is under review.
Whether any of these peptides is appropriate for you depends on your individual goals, your health history, your hormone levels, and the judgment of a licensed healthcare provider. This article is a starting point for education, not a guide to self-treatment. If you’re curious about what peptide therapy might look like for your situation, the best first step is a conversation with a knowledgeable clinician.
This content is for educational purposes only and is not a substitute for advice from a licensed medical provider. All compounded formulations are prepared by Olympia Pharmaceuticals under cGMP guidelines and with oversight by national and state pharmacy boards. Always consult with a medical professional before beginning any new regimen or care plan.
